Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
TECH
Bio-Techne Corporation
Bio-Techne's core business includes recombinant proteins and enzymes used as highly characterized reagents across life-science workflows.
|
$10.05B |
$64.60
-0.05%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$9.73B |
$25.00
+1.03%
|
|
BAX
Baxter International Inc.
Novum IQ infusion platform is a medical device platform core to Baxter's Medical Devices & Equipment offerings.
|
$9.71B |
$18.91
+1.31%
|
|
RNA
Avidity Biosciences, Inc.
Direct product modality: oligonucleotide therapeutics (AOC platform) delivering RNA payloads.
|
$9.21B |
$71.58
+0.02%
|
|
HSIC
Henry Schein, Inc.
Henry Schein directly distributes dental equipment to dental practices, aligning with its core product offerings.
|
$9.13B |
$75.27
-0.31%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
BIO
Bio-Rad Laboratories, Inc.
Bio-Rad directly manufactures and sells diagnostic instruments and related equipment used in clinical laboratories.
|
$8.85B |
$327.17
-1.52%
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$8.81B |
$178.98
+0.52%
|
|
HIMS
Hims & Hers Health, Inc.
Laboratory testing & advisory services core to in-house lab capabilities.
|
$8.68B |
$38.41
+3.55%
|
|
DVA
DaVita Inc.
DaVita operates clinical laboratory testing facilities and diagnostic services as part of its dialysis and kidney care offerings.
|
$8.59B |
$120.13
-1.02%
|
|
AHR
American Healthcare REIT, Inc.
Healthcare Services & Facilities: reflects management and operation of healthcare facilities within the portfolio.
|
$8.51B |
$50.49
-0.02%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$8.50B |
$72.68
+0.03%
|
|
CORT
Corcept Therapeutics Incorporated
Corcept develops and commercializes oral small-molecule cortisol modulators (Korlym, relacorilant) for hypercortisolism and oncology, fitting 'Oral Small Molecule Therapeutics'.
|
$8.41B |
$79.83
+0.04%
|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT is Blueprint Medicines' flagship oncology/hematology drug; directly produced and marketed, fitting Biotech - Oncology.
|
$8.27B |
$129.46
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.16B |
$123.82
+0.01%
|
|
CYTK
Cytokinetics, Incorporated
Cytokinetics' core programs target cardiovascular diseases (aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil and ulacamten), making 'Cardiovascular Drugs' the primary investable theme.
|
$8.15B |
$68.16
+0.01%
|
|
MOH
Molina Healthcare, Inc.
MOH primarily provides health insurance products (Medicaid, Medicare, Marketplace) including integrated dual-eligible plans.
|
$8.04B |
$148.32
+1.06%
|
|
AVTR
Avantor, Inc.
Avantor provides Laboratory Testing & Advisory Services, aligning with outsourced testing and regulatory support offerings.
|
$8.00B |
$11.74
-0.93%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$7.98B |
$57.72
+0.02%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$7.91B |
$125.79
-1.90%
|
|
NUVL
Nuvalent, Inc.
Nuvalent is a oncology-focused biotechnology company developing targeted cancer therapies (ROS1/ALK inhibitors), fitting Biotech - Oncology.
|
$7.86B |
$109.15
-0.65%
|
|
LNC
Lincoln National Corporation
LNC provides disability insurance as part of its group protection/employee benefits offerings.
|
$7.84B |
$41.36
+0.85%
|
|
MASI
Masimo Corporation
Primary revenue comes from patient monitoring devices and systems sold to healthcare providers.
|
$7.82B |
$143.94
-0.01%
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$7.53B |
$150.81
-0.11%
|
|
BRKR
Bruker Corporation
Bruker directly manufactures diagnostic instrumentation and analytical equipment such as MALDI Biotyper and other diagnostic/imaging instruments.
|
$7.44B |
$49.02
-0.63%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
MRUS
Merus N.V.
Company develops multispecific antibody therapeutics for oncology, including lead candidates like petosemtamab and BIZENGRI.
|
$7.27B |
$96.08
-0.01%
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Rhythm's core business is developing and commercializing therapies for ultra-rare diseases (e.g., setmelanotide for MC4R pathway deficiencies, BBS), a hallmark of rare-disease biotech.
|
$7.13B |
$107.45
-1.20%
|
|
STVN
Stevanato Group S.p.A.
Directly manufactures Prefillable Syringes used for sterile biologic and small-molecule injections.
|
$6.94B |
$23.13
+1.00%
|
|
PTCT
PTC Therapeutics, Inc.
Inflammation platforms (vatiquinone, utreloxastat) indicate immunology therapeutics focus.
|
$6.85B |
$86.24
-0.01%
|
Showing page 6 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
